Press releases

GeNeuro: financial information and business update for the third quarter 2020

Geneva, Switzerland, October 19, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 third quarter cash position and issued a business update.

https://geneuro.ch/data/news/GeNeuro-PR-Q3-2020-EN-101920.pdf

GeNeuro Reports 2020 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, September 29, 2020 at 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2020 and provided a corporate update.

https://geneuro.ch/data/news/GeNeuro-PR-1H2020-Results-ENG.pdf

GeNeuro and the Karolinska Institutet’s Academic Specialist Center (ASC) Present Temelimab Neurodegeneration Prevention Study at MSVirtual2020

Geneva, Switzerland, September 14, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a presentation by Professor Fredrik Piehl of the Karolinska Institutet’s Academic Specialist Center (ASC) at MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting) provided the rationale and outline on the Phase 2 ProTEct-MS clinical study of temelimab initiated earlier this year.

https://geneuro.ch/data/news/GeNeuro-PR-Presentation-at-8th-ACTRIMS-ECTRIMS-2020-EN-vf.pdf

GeNeuro and the Karolinska Institutet’s Academic Specialist Center (ASC) to Present ProTEct-MS Study of Temelimab at MSVirtual2020

Geneva, Switzerland, September 8, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the company and the Karolinska Institutet’s Academic Specialist Center (ASC) will present the rationale of its new Phase 2 study at MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting), held September 11-13, 2020. The trial, which is evaluating the administration of temelimab in patients with relapsing MS to address disease progression independent of relapses following treatment with rituximab, is being conducted at the Karolinska Institutet’s Academic Specialist Center, Stockholm, Sweden.

https://geneuro.ch/data/news/GeNeuro-PR-8th-ACTRIMS-ECTRIMS-2020-eng.pdf

GeNeuro: financial information and business update for the second quarter 2020

Geneva, Switzerland, July 23, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 second quarter cash position and issued a business update.

https://geneuro.ch/data/news/2020.07.23-GeNeuro-PR-Q2-2020-EN-Final.pdf

GeNeuro announces the publication in Science Advances of data establishing clear link between human endogenous retroviral proteins and psychotic disorders

Geneva, Switzerland, 21 July 2020 – 08:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced data showing the etiological interplay between human endogenous retroviral (HERV) proteins and the emergence of psychotic phenomena in mice.

https://geneuro.ch/data/news/2020.07.21-GeNeuro-PR-Fondamental-EN-final.pdf